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Multifocal Myositis and Elevated CPK associated with the use of Ustekinumab for Hidradenitis
Suppurativa

Dear Editor, ustekinumab (UST) is a human interleukin (IL)-12/IL-23 monoclonal antibody that has
been approved by the Food and Drug Administration (FDA) to treat moderate to severe plaque
psoriasis, psoriatic arthritis, and Crohn’s disease. Off-label use of UST has shown promising results
for hidradenitis suppurativa (HS) in patients that have failed therapy with adalimumab, the only FDA
approved treatment for HS.1 Common adverse reactions of UST include headache, fatigue, and upper
respiratory tract infections and are generally mild.1 We report a patient with poorly controlled HS who
experienced new onset myositis during treatment with UST.
Our patient was a 49-year-old female with a three-year history of Hurley Stage III HS and a past
medical history which included metabolic syndrome and class I obesity. She had no prior personal or
family history of autoimmune disorders. Moderate improvement of HS was seen with adalimumab
and infliximab, however, both were discontinued due to complications from polymicrobial, multidrug
resistant infections. Despite promising results after three rounds of CO2 laser excision and surgical
deroofing, she continued to have an average of one to two acute HS flares per month. To further
maintain and stabilize flares between CO2 laser therapy sessions, subcutaneous UST was initiated at a
standard dose of 90 mg administered at weeks 0, 4, and 12. The patient initially tolerated UST and
noticed a reduction in frequency of HS flares, but shortly after the third injection, the patient reported
significant functional limitation due to palmar erythema, myalgia, swelling of the proximal
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extremities, and generalized muscle weakness. An electromyography (EMG) was abnormal,
demonstrating low amplitude and short duration motor units with normal recruitment in the bilateral
bicep muscles and longer duration motor units in the extensor carpi radialis and lateral gastrocnemius
muscles. There was no evidence of muscle membrane irritablility, making an underlying
inflammatory condition unlikely. These findings along with an elevated creatine phosphokinase
(CPK) three times the normal limit were consistent with a mild, non-irritable drug-associated
myositis. The timing to onset of symptoms was 2 days after the third (12th week) injection. Upon
discontinuation of UST, CPK levels normalized with resolution of symptoms 12 weeks from
symptom(s) onset.
This case demonstrates the unexpected development of multifocal myositis associated with the use of
UST in an HS patient. Drug-induced myositis (DIM) is defined as muscle damage, and/or muscle
breakdown due to direct myotoxicity, indirect damage, or an immunologically induced inflammatory
reaction.2 Manifestations of DIM include myalgias, generalized symmetrical weakness, and proximal
muscle soreness.2 Diagnosis is based on the clinical examination and diagnostic tests such as CPK
levels, autoantibodies, EMG, and muscle biopsies. Symptoms are typically temporary and reversed by
drug discontinuation. The clinical resolution of symptoms after discontinuation of UST therapy, with
no evidence of muscle membrane irritability per EMG findings, in addition to a negative family and
personal history of autoimmune disorders does not support the diagnoses of inflammatory and/or
autoimmune myopathies.
According to Eudraviligance, there has been 9 previously reported cases of UST associated myositis.3
The FDA adverse event reporting system, MedWatch, has 14 documented cases of UST associated
myositis since 2012, including 3 that were disabiling and 4 that led to hospitalization.4 Naranjo’s
algorithm score supports a probable adverse drug reaction given the previous reports of this occurance
in pharmacovigilance databases, the temporal sequence of events, and having no other reasonable
explanation of this event from our patient’s clinical history and characteristics. Concomitant
medications in this patient included metformin, colchicine, spironolactone, and zinc. Of those
medications, colchicine has been previously associated with myopathy, although this presentation is
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usually slow and painless after prolonged treatment. Our patient was taking 0.6 mg of colchine daily
for the past two years and continued taking colchicine during this episode of myositis. Colchicine
myopathy risk is increased with concominant use of CYP3A4 inhibitors, including macrolide
antibiotics, cyclosporine, -azoles, and protease inhibitors.5 Chronic kidney disease (CKD) is a major
predisposing risk factor, leading to plasma colchicine toxicity. Our patient denied a history of CKD at
onset of DIM related symptoms.5
UST associated myositis is rarely reported outside of pharmacoviligiance databases and has not been
previously reported during off-label use for HS. Given the growing use of UST for the management
of refractory HS, it is important for clinicians to consider the potential adverse effect of myositis.
Further research is needed to evaluate the pathophysiology and prevalence of UST associated
myositis.
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